Literature DB >> 21786793

Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.

Aleem Gangjee1, Ying Zhao, Ernest Hamel, Cara Westbrook, Susan L Mooberry.   

Abstract

(R,S)-1 is a potent antimitotic compound. (R)-1·HCl and (S)-1·HCl were synthesized from (R)- and (S)-3-methyladipic acid. Both enantiomers were potent inhibitors of cell proliferation and caused cellular microtubule loss and mitotic arrest. They inhibited purified tubulin assembly and the binding of [(3)H]colchicine to tubulin, with (S)-1 being about twice as potent. Cytotoxicity against 60 tumor cell lines, however, indicated that the (S)-isomer was 10- to 88-fold more potent than the (R)-isomer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21786793      PMCID: PMC3184787          DOI: 10.1021/jm2007722

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

2.  Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.

Authors:  Aleem Gangjee; Ying Zhao; Lu Lin; Sudhir Raghavan; Elizabeth G Roberts; April L Risinger; Ernest Hamel; Susan L Mooberry
Journal:  J Med Chem       Date:  2010-10-25       Impact factor: 7.446

3.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.

Authors:  Tam Luong Nguyen; Connor McGrath; Ann R Hermone; James C Burnett; Daniel W Zaharevitz; Billy W Day; Peter Wipf; Ernest Hamel; Rick Gussio
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

4.  aS,7S-absolute configuration of natural (-)-colchicine and allo-congeners.

Authors:  A Brossi; O Boyé; A Muzaffar; H J Yeh; V Toome; B Wegrzynski; C George
Journal:  FEBS Lett       Date:  1990-03-12       Impact factor: 4.124

5.  Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

Authors:  Gabriella Ferrandina; Gian Franco Zannoni; Enrica Martinelli; Amelia Paglia; Valerio Gallotta; Simona Mozzetti; Giovanni Scambia; Cristiano Ferlini
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

6.  Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.

Authors:  Charles Dumontet; Sylvie Isaac; Pierre-Jean Souquet; Françoise Bejui-Thivolet; Yves Pacheco; Nadine Peloux; Anthony Frankfurter; Richard Luduena; Maurice Perol
Journal:  Bull Cancer       Date:  2005-02       Impact factor: 1.276

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.

Authors:  Rafael Rosell; Giorgio Scagliotti; Kathleen D Danenberg; Reginald V N Lord; Gerold Bepler; Silvia Novello; Janine Cooc; Lucio Crinò; José Javier Sánchez; Miquel Taron; Corrado Boni; Filippo De Marinis; Maurizio Tonato; Maurizio Marangolo; Felice Gozzelino; Franceso Di Costanzo; Massimo Rinaldi; Dennis Salonga; Craig Stephens
Journal:  Oncogene       Date:  2003-06-05       Impact factor: 9.867

9.  Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity.

Authors:  Gary M Chinigo; Mikell Paige; Scott Grindrod; Ernest Hamel; Sivanesan Dakshanamurthy; Maksymilian Chruszcz; Wladek Minor; Milton L Brown
Journal:  J Med Chem       Date:  2008-07-09       Impact factor: 7.446

10.  The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

Authors:  April L Risinger; Evelyn M Jackson; Lisa A Polin; Gregory L Helms; Desiree A LeBoeuf; Patrick A Joe; Elizabeth Hopper-Borge; Richard F Ludueña; Gary D Kruh; Susan L Mooberry
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  10 in total

1.  Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.

Authors:  R M Hartley; J Peng; G A Fest; S Dakshanamurthy; D E Frantz; M L Brown; S L Mooberry
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

Review 2.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

3.  How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site.

Authors:  Chenxiao Da; Susan L Mooberry; John T Gupton; Glen E Kellogg
Journal:  J Med Chem       Date:  2013-09-09       Impact factor: 7.446

4.  Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents.

Authors:  Aleem Gangjee; Ying Zhao; Sudhir Raghavan; Cristina C Rohena; Susan L Mooberry; Ernest Hamel
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

5.  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Authors:  Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2014-05-14       Impact factor: 3.641

6.  Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.

Authors:  Ravi Kumar Vyas Devambatla; Ojas A Namjoshi; Shruti Choudhary; Ernest Hamel; Corena V Shaffer; Cristina C Rohena; Susan L Mooberry; Aleem Gangjee
Journal:  J Med Chem       Date:  2016-06-07       Impact factor: 7.446

7.  Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

Authors:  Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2021-02-12       Impact factor: 3.641

8.  The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.

Authors:  Weiguo Xiang; Tasdique M Quadery; Ernest Hamel; Lerin R Luckett-Chastain; Michael A Ihnat; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2020-11-24       Impact factor: 3.641

Review 9.  Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?

Authors:  Marta Szumilak; Anna Wiktorowska-Owczarek; Andrzej Stanczak
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

10.  Janus Compounds, 5-Chloro-N⁴-methyl-N⁴-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects.

Authors:  Cristina C Rohena; April L Risinger; Ravi Kumar Vyas Devambatla; Nicholas F Dybdal-Hargreaves; Roma Kaul; Shruti Choudhary; Aleem Gangjee; Susan L Mooberry
Journal:  Molecules       Date:  2016-12-02       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.